Prednison 5 mg GALEN® Tabletten

DRUG3 trials

Sponsors

Priovant Therapeutics Inc., Exelixis Inc., Novartis Pharma AG

Conditions

Metastatic Castration-Resistant Prostate CancerPSMA-positive mCRPC with prior exposure to at least one prior ARPIactive non-infectious uveitis (intermediate uveitispanuveitis)posterior uveitis

Phase 1

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Not yet recruitingCTIS2025-521859-23-00

Novartis Pharma AGPSMA-positive mCRPC with prior exposure to at least one prior ARPI

Target: 61Updated: 2026-03-06

Phase 3

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer

Active, not recruitingCTIS2024-516481-11-00

Exelixis Inc.Metastatic Castration-Resistant Prostate Cancer

Start: 2020-09-22Target: 203Updated: 2025-12-04

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis

Active, not recruitingCTIS2024-515089-15-00

Priovant Therapeutics Inc.active non-infectious uveitis (intermediate uveitis, panuveitis), posterior uveitis

Start: 2025-02-28Target: 105Updated: 2025-12-18